Singulair (montelukast) is a small molecule pharmaceutical. Montelukast was first approved as Singulair on 1998-02-20. It is used to treat allergic rhinitis perennial and asthma in the USA. The pharmaceutical is active against cysteinyl leukotriene receptor 1. In addition, it is known to target uracil nucleotide/cysteinyl leukotriene receptor and cytochrome P450 2C8. Singulair's patent is valid until 2022-10-24 (FDA).
|Indication||allergic rhinitis perennial, asthma|
|Drug Class||Antiasthmatics/antiallergics: leukotriene receptor antagonists|